Financings

Annovation Biopharma Inc. raised $8 million in a Series A financing.

Biotie Therapies Oy received $38.3 million from H. Lundbeck A/S and existing institutional shareholders.

Regulus Therapeutics Inc. set the terms for its IPO, planning to raise $50 million.

Sequenom Inc. intends to offer $100 million of convertible senior notes due 2017 in a private offering.

Tranzyme Pharma Inc. is seeking to raise $10 million in a registered direct offering.

Vascular Pharmaceuticals Inc. completed a $16 million Series A equity financing.

Deals

Summit plc will collaborate with Bristol-Myers Squibb Co. on its Seglin technology.

SFJ Pharmaceuticals Group will work with Pfizer Inc. to conduct a Phase III trial of dacomitinib.

Ampio Pharmaceuticals Inc. entered an agreement with EthyPharm SA to manufacture Zertane.

Cerus Corp. partnered with the American Red Cross and Blood Systems Inc. to commercialize Intercept plasma for thrombotic thrombocytopenic purpura in the U.S.

Islet Sciences Inc. licensed technology to commercialize expanding pancreatic islets from the UCLA.

Oncodesign SA is working with Sanofi SA using its Nanocyclix technology in kinase target programs.

. . . And More

Genzyme received FDA approval for Aubagio, a new oral therapy for relapsing multiple sclerosis.

Geron Corp. will stop a Phase II study of imetelstat in metastatic HER2-negative breast cancer.

Palatin Technologies Inc.'s partner AstraZeneca plc will discontinue development of AZD2820 in obesity.

Pfizer Inc. will develop generics in China with Zhejiang Hisun Pharmaceutical Co. Ltd.

Zalicus Inc. terminated its program for Synavive after a Phase IIb trial in rheumatoid arthritis failed.